How This New Biotech Billionaire Outmaneuvered Merck In China

How This New Biotech Billionaire Outmaneuvered Merck In China

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best seller–and its surging stock just made her a billionaire.

MSD, AZ partner LaNova bought by Sino Biopharm for $951m

LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million

Sino Biopharm Taking Over Cancer Treatment Firm for $951 Million

Sino Biopharmaceutical Ltd. said it would take over the privately held Chinese biotech company LaNova Medicines Ltd.

Cancer drugmaker LaNova to sell to China’s Sino Biopharm

Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.